Adial Pharmaceuticals IncADIL
ASignal's systematic analysis rates ADIL as Neutral.
Reflects the latest available analysis · analyzed Aug 20, 2026
The case on ADIL
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive MACD momentum with MACD above signal line
- Strong cash position with no debt
- High current and quick ratios indicating liquidity strength
- Price above 20-day and 50-day moving averages
- RSI at 75.74 indicating overbought conditions
- Negative return on equity (-2011.66%)
- Negative operating cash flow ($-11.13M)
- Negative free cash flow ($-4.23M)
- Negative price-to-book and EV/EBITDA ratios
- No Reddit mentions suggesting low retail interest
See the full verdict on ADIL
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ADIL
Most investors never get a second opinion, let alone several. ASignal runs ADIL past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.